Correlation Between Genmab AS and Pulmatrix

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Genmab AS and Pulmatrix at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Genmab AS and Pulmatrix into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Genmab AS and Pulmatrix, you can compare the effects of market volatilities on Genmab AS and Pulmatrix and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Genmab AS with a short position of Pulmatrix. Check out your portfolio center. Please also check ongoing floating volatility patterns of Genmab AS and Pulmatrix.

Diversification Opportunities for Genmab AS and Pulmatrix

0.07
  Correlation Coefficient

Significant diversification

The 3 months correlation between Genmab and Pulmatrix is 0.07. Overlapping area represents the amount of risk that can be diversified away by holding Genmab AS and Pulmatrix in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Pulmatrix and Genmab AS is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Genmab AS are associated (or correlated) with Pulmatrix. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Pulmatrix has no effect on the direction of Genmab AS i.e., Genmab AS and Pulmatrix go up and down completely randomly.

Pair Corralation between Genmab AS and Pulmatrix

Given the investment horizon of 90 days Genmab AS is expected to under-perform the Pulmatrix. But the stock apears to be less risky and, when comparing its historical volatility, Genmab AS is 2.56 times less risky than Pulmatrix. The stock trades about -0.38 of its potential returns per unit of risk. The Pulmatrix is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest  209.00  in Pulmatrix on June 30, 2024 and sell it today you would earn a total of  5.00  from holding Pulmatrix or generate 2.39% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Genmab AS  vs.  Pulmatrix

 Performance 
       Timeline  
Genmab AS 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Genmab AS has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Genmab AS is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.
Pulmatrix 

Risk-Adjusted Performance

4 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Pulmatrix are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very weak essential indicators, Pulmatrix displayed solid returns over the last few months and may actually be approaching a breakup point.

Genmab AS and Pulmatrix Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Genmab AS and Pulmatrix

The main advantage of trading using opposite Genmab AS and Pulmatrix positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Genmab AS position performs unexpectedly, Pulmatrix can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pulmatrix will offset losses from the drop in Pulmatrix's long position.
The idea behind Genmab AS and Pulmatrix pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Other Complementary Tools

Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Commodity Directory
Find actively traded commodities issued by global exchanges
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Stocks Directory
Find actively traded stocks across global markets